课题基金 / 基金详情

Molecular basis and generation of new compounds for probing phosphorylation-mediated signaling pathways

Molecular basis and generation of new compounds for probing phosphorylation-mediated signaling pathways
用于探测磷酸化介导的信号通路的新化合物的分子基础和生成
批准号:
06507001
负责人:
HIDAKA Hiroyoshi
金额:
$19.14万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1996

项目摘要

项目成果

HIDAKA Hiroyoshi的其他基金

相似基金

相关文献

中文摘要
翻译
有证据表明,蛋白激酶参与了多种细胞过程,如去极化偶联的平滑肌收缩,促分泌剂刺激的分泌细胞释放生物活性物质,以及有丝分裂原激活的细胞生长。蛋白激酶抑制剂在研究蛋白激酶的生理学意义上似乎是有用的,而且部分蛋白激酶可能用作药物。这一假设已经被我们的H系列蛋白激酶抑制剂H-89、H-7、KN-62和HA-1077所证实。本研究的目的是阐明它们的作用,并为蛋白激酶抑制剂的分子设计提供理论依据。所取得的结果总结如下1.测定了蛋白激酶A与H-7,8,89的络合物的晶体结构(Bossmeyer et.艾尔JBC,1996)。这表明,蛋白质的腺嘌呤口袋很好地容纳了H系列化合物中的异奎诺激动素磺酰胺。似乎很有可能t…学位添加到异奎诺激动磺酰胺上的化学结构对化合物结合的贡献更多地决定了它们对蛋白激酶的选择性。HA-1077对包括肌球蛋白轻链激酶在内的多种蛋白激酶具有非特异性抑制作用,用于治疗蛛网膜下腔出血后脑血管痉挛。通过在HA-1077上添加一些化学基团,例如它的甲基化,这些新化合物被发现显著地改变为某些蛋白激酶的特异性抑制剂。结合上述发现,有可能通过改变连接在异喹啉磺酰胺核心上的化学基团来修饰H系列化合物。根据构效关系,我们发现异喹啉磺酰胺对KN-62细胞的钙/钙调蛋白依赖性蛋白激酶抑制也是必不可少的,虽然该化合物与钙调蛋白竞争,但不与ATP竞争。我们认为,H系列化合物是新的蛋白激酶抑制剂的种子化合物,当获得更多关于蛋白激酶结构的信息时,它们将结出更多的果实。较少
英文摘要
Evidence accum ulated that protein kinases are involved in a variety of cellular processes such as depolarization -coupled smooth muscle contraction, secretagogues-stimulated release of biologically active substances from secretory cells, and mitogen-activated cell growth. Protein kinase inhibitors seem to be usful in studying physiological significance of protein kinases and part of tham probably works as medicines. This hypothesis has been, if any, proved with our H-series protein kinase inhibitors, H-89, H-7, KN-62, and HA-1077. Our goal of this research is to elucidate their actions and to construct some theory for molecular designing of protein kinase inhibitors. The results obtained are summarized as described below.1. The crystal structure of protein kinase A complex with H-7,8,89 was deterimined (Bossmeyer et. al. JBC,1996). This revealed that the adenine pocket of the protein accommodates well the isoquinokinesulfonamide of H-series compounds. It seems likely that the degree t … More o which the chemical structure added to the isoquinokinesulfonamide contributes to binding of the compounds determines their selectivity for protein kinases.2. HA-1077 shows a non-specific inhibition for a variety of protein kinases including myosin light chain kinase and is used as medicine for the treatment of cerebral vasospasm after subarachnoidal hemorrhage. By addition of some chemical groups to HA-1077, for example its methylation, such new compounds were found to change remarkably into specific inhibitors of some protein kinase. Combined with the findings described above, it is possible to amend H-series compounds by altering their chemical groups attached to the isoquinolinesulfonamide core.3. Based on structure-activity relationship, it was found that an isoquinolinesulfonamide was also indispensable for KN-62 to show calcium/calmodulin-dependent protein kinase inhibition, although the compound competed with calmodulin, but not with ATP.We consider that H-series compounds are seed compounds for new protein kinase inhibitors, and that they will bear more fruits when more information conceruing the structures of protein kinases are available. Less
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
H.Yokokura, Y.Okada, O.Terada, andH.Hidaka: "HMN-709, a chlorobenzenesulfonamide derivative and a new, membrane-permeable calmodulin antagonist." Jpn.J.Pharmacol.72. 127-135 (1996)
H.Yokokura、Y.Okada、O.Terada 和 H.Hidaka:“HMN-709,一种氯苯磺酰胺衍生物,一种新型膜渗透性钙调蛋白拮抗剂。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
H.Hidaka: "Protein Kinase inhibitors" Essays in Biochemistry. 28. 73-97 (1994)
H.Hidaka:“蛋白激酶抑制剂”生物化学论文。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
H.Yokokura: "HMN-709, a chlorobenzenesulfonamide derivative and a new, membrane-permeable calmodulin antagonist." Jpn. J. Pharmacol.72. 127-135 (1996)
H.Yokokura:“HMN-709,一种氯苯磺酰胺衍生物,一种新型膜渗透性钙调蛋白拮抗剂。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 19 条
    ELUCIDATION OF THE INTRACELLULAR CALCIUM SIGNAL TRANSDUCTION WITH THE MOLECULAR PHARMACOLOGICAL APPROARCH
    • 批准号:
      06404019
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $22.21万
    • 财政年份:
      1994
    • 负责人:
      HIDAKA Hiroyoshi
    • 依托单位:
    Nuclear magnetic resonance studies of calcyclin and annexin XI.
    • 批准号:
      06044105
    • 项目类别:
      Grant-in-Aid for international Scientific Research
    • 资助金额:
      $7.04万
    • 财政年份:
      1994
    • 负责人:
      HIDAKA Hiroyoshi
    • 依托单位:
    Establishment of the pharmacological sciences to elucidate the signal transduction system.
    • 批准号:
      04304030
    • 项目类别:
      Grant-in-Aid for Co-operative Research (A)
    • 资助金额:
      $9.6万
    • 财政年份:
      1992
    • 负责人:
      HIDAKA Hiroyoshi
    • 依托单位:
    The Development of the Strategy for the Presumption of the Tertiary Structure of Protein Kinases by Specific Inhibitors
    • 批准号:
      02557009
    • 项目类别:
      Grant-in-Aid for Developmental Scientific Research (B)
    • 资助金额:
      $7.42万
    • 财政年份:
      1990
    • 负责人:
      HIDAKA Hiroyoshi
    • 依托单位:
    国内基金
    海外基金
    抑制Protein Kinase D促进胚胎干细胞自我更新的分子机制研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      54万元
    • 批准年份:
      2022
    • 负责人:
      叶守东
    • 依托单位: